TABLE 1.

Clinical trial identifiers, drug class and targets.

Drug class	Target	Action/effect	Trial identifier	Sponsor/location
ER agonist	Estrogen Receptor	Increase estrogen and its effects	NCT04359329	Stony Brook University Hospital, NY, USA
ER modulator	Estrogen Receptor	Decreases estrogen production Increases testosterone production	NCT04389580*	Kafrelsheikh University Egypt
P4 hormone	Progesterone Receptor	Increase progesterone and its effects	NCT04365127	Cedars Sinai Medical Center, CA, USA
E2/P4 combined	Estrogen receptor and progesterone receptor		NCT04539626	Mexico
Anti-Androgens	Androgen Receptor	Decrease androgens/androgen signaling	NCT04374279 NCT04475601 NCT04509999 NCT04446429	Johns Hopkins, MD, USA Sweden USA Brazil
LHRH antagonist	GnRH	Decrease androgens	NCT04397718	Los Angeles, Brooklyn, Manhattan, Seattle, USA
TMPRSS2 inhibitor	TMPRSS2	Decrease TMPRSS2 action	NCT04353284 NCT04338906* NCT04374019 NCT04321096 NCT04355052* NCT04352400 NCT04355026 NCT04273763* NCT04340349*	Yale, USA Heinrich-Heine University, Germany University of Kentucky, KY, USA University of Aarhus, Denmark Sheba Medical Center, Israel University Hospital Padova, Italy General and Teaching Hospital Celje, Slovenia Wenzhou Medical University, China Instituto Nacional de Rehabilitacion, Mexico
Aldosterone antagonist	Androgen receptor	Decrease androgen signaling	NCT04345887	Istanbul University, Turkey

*Denotes trial in combination with other treatment.